Friday, July 10, 2026
🇺🇸 FDA

pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis

Istituto Gentili Italia

Istituto Gentili S.r.l.

Istituto Gentili Italia clinical programs — 34 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT HQ
1917 Founded
121 Employees
EMA registrant Type
Company details
Status
Public
HQ
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
Founded
1917
Employees
121
Programs
50
Drugs
114
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Istituto Gentili Italia projects

34 ClinicalTrials.gov programs sponsored by Istituto Gentili Italia.

Istituto Gentili Italia has 34 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

34 programs

Clinical programs

  1. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    PSMA PET/CT positive advanced/metastatic tumours

    phase 2 small molecule active

    1 trial

  2. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    Oligometastatic prostate carcinoma

    phase 2 small molecule active

    1 trial

  3. 5MILLE_CT1

    Istituto Gentili S.r.l.

    White-Sutton syndrome (POGZ-Related Disorder)

    phase 2 small molecule active

    1 trial

  4. 68Ga-FAPI-46

    Istituto Gentili S.r.l.

    oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT

    phase 2 small molecule active

    1 trial

  5. AMINOHIPPURIC ACID for Membranous nephropathy

    Istituto Gentili S.r.l.

    Membranous nephropathy

    phase 2 small molecule active

    1 trial

  6. APLOaß-NB

    Istituto Gentili S.r.l.

    Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.

    phase 2 small molecule active

    1 trial

  7. Argon/Oxygen mixture, OXYGEN

    Istituto Gentili S.r.l.

    Cardiac arrest

    phase 2 small molecule active

    1 trial

  8. CHIMERA

    Istituto Gentili S.r.l.

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  9. CYCLOPHOSPHAMIDE for Inoperable locally advanced or…

    Istituto Gentili S.r.l.

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial

  10. DC-VACCINE_IRSTIRCCS for Stage IV colorectal cancer

    Istituto Gentili S.r.l.

    Stage IV colorectal cancer

    phase 2 small molecule active

    1 trial

  11. DURVALUMAB, Ceralasertib

    Istituto Gentili S.r.l.

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  12. ElechtraPlatinum

    Istituto Gentili S.r.l.

    relapsing vulvar carcinoma already subjected to multiple treatments

    phase 2 small molecule active

    1 trial

  13. Gazyvaro 1 for Idiopathic Nephrotic Syndrome

    Istituto Gentili S.r.l.

    Idiopathic Nephrotic Syndrome

    phase 2 small molecule active

    1 trial

  14. IRST100.42

    Istituto Gentili S.r.l.

    neuroendocrine tumors, soft tissue sarcoma

    phase 2 small molecule active

    1 trial

  15. IRST100.59

    Istituto Gentili S.r.l.

    Solid tumors

    phase 2 other active

    1 trial

  16. IRST100.60

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  17. IRST153.09

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  18. IRST162.14

    Istituto Gentili S.r.l.

    Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

    phase 2 small molecule active

    1 trial

  19. IRST185.04

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  20. IRST191.05

    Istituto Gentili S.r.l.

    Glioblastoma

    phase 2 small molecule active

    1 trial

  21. IRST204.09

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  22. KEYTRUDA for Locally recurrent, inoperable…

    Istituto Gentili S.r.l.

    Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

    phase 2 small molecule active

    1 trial

  23. LOSARTAN

    Istituto Gentili S.r.l.

    Osteogenesis Imperfecta

    phase 2 small molecule active

    1 trial

  24. METFORMIN

    Istituto Gentili S.r.l.

    bone sarcoma

    phase 2 small molecule active

    1 trial

  25. Neulasta 6 mg solution for injection

    Istituto Gentili S.r.l.

    Severe chronic neutropenia (SCN)

    phase 2 small molecule active

    1 trial

  26. RESCUE-HUB

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  27. RESTORE

    Istituto Gentili S.r.l.

    decompensated cirrhosis

    phase 2 small molecule active

    1 trial

  28. SELUMETINIB for Metastatic breast cancer

    Istituto Gentili S.r.l.

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  29. Silycus®

    Istituto Gentili S.r.l.

    Cushing's disease

    phase 2 small molecule active

    1 trial

  30. Stivarga 40 mg film-coated tablets

    Istituto Gentili S.r.l.

    grade 1, 2 and 3 meningioma

    phase 2 small molecule active

    1 trial

  31. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

  32. Trimeton / soluzione iniettabile for Primary Membranous Nephropathy

    Istituto Gentili S.r.l.

    Primary Membranous Nephropathy

    phase 2 small molecule active

    1 trial

  33. UID 4270

    Istituto Gentili S.r.l.

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  34. Ultravist 370 mg/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Patients with breast lesions undergoing further examination

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Istituto Gentili Italia have?

34 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.